Last reviewed · How we verify
NCT05642286
Clinical Study of Endovascular Interventional Surgical Instrument Control System and Related Consumables in Percutaneous Coronary Intervention
NA trial testing ALLVAS® robotic-assisted PCI in Percutaneous Coronary Intervention in 218 participants. Status unknown.
30 November 2024
Quick facts
| Lead sponsor | Shanghai Operation Robot Co., Ltd. |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 218 |
| Start date | 1 December 2022 |
| Primary completion | 30 November 2024 |
| Estimated completion | 31 December 2024 |
Drugs / interventions tested
- ALLVAS® robotic-assisted PCI
Conditions studied
- Percutaneous Coronary Intervention — all drugs for Percutaneous Coronary Intervention →
- Coronary Heart Disease — all drugs for Coronary Heart Disease →
- Robotic Surgical Procedures — all drugs for Robotic Surgical Procedures →
Sponsor
Shanghai Operation Robot Co., Ltd.
Who can join
Adults 18 to 75, any sex, with Percutaneous Coronary Intervention or Coronary Heart Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this study is to evaluate the safety and effectiveness of endovascular interventional surgery instrument control system （ALLVAS®robot）and supporting consumables for coronary artery interventional surgery. Participants will will complete coronary intervention surgery with the assistance of robot system（ALLVAS®robot）, and evaluate the effect of the use effect of robots and clinical treatment after surgery
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05642286
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Percutaneous Coronary Intervention
Currently open trials in the same condition.
- NCT07231939 — Use of Flozins (Empagliflozin/Dapagliflozin) for Prevention of AKI · recruiting
- NCT07378163 — Study on the Preferences for PCI Implantation Devices Among Doctors and Patients · recruiting
- NCT07378137 — Comparing the Components of Composite Endpoints for Healthcare Providers and Patients · recruiting
- NCT06878729 — Antegrade Dissection and Re-entry Versus Retrograde Strategy in CTO PCI · NA · recruiting
- NCT07446023 — IVUS-FFR Accuracy for Coronary Stenosis · NA · recruiting
Other Shanghai Operation Robot Co., Ltd. trials
Trials by the same sponsor.
- NCT05625711 — Clinical Study of Endovascular Interventional Surgical Instrument Control System and Related Consumables in Lower Extrem · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05642286 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Operation Robot Co., Ltd.
- Last refreshed: 8 December 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05642286.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing